ReviewSeminars in cancer biology2009
Drug resistance associated with antiangiogenesis therapy.
Review in Seminars in cancer biology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 69 citations in OpenAlex.
- Inflammation-associated drug resistance and tumor growth in TNBC.Frontiers in immunology · 2025Review
- Delineation of the androgen-regulated signaling pathways in prostate cancer facilitates the development of novel therapeutic approaches.Current opinion in pharmacology · 2018Review
- Stromal cells in breast cancer as a potential therapeutic target.Oncotarget · 2018Review
- Review
- Pre-clinical longitudinal monitoring of hemodynamic response to anti-vascular chemotherapy by hybrid diffuse optics.Biomedical optics express · 2017Article
- CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency.Cancer science · 2017Article
- Targeting Angiogenesis in Biliary Tract Cancers: An Open Option.International journal of molecular sciences · 2017Review
- Angiopoietins Modulate Survival, Migration, and the Components of the Ang-Tie2 Pathway of Chronic Lymphocytic Leukaemia (CLL) Cells In Vitro.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2016Article
- Efficacy of traditional Chinese medicine in treating cancer.Biomedical reports · 2016Article
- Pien Tze Huang Inhibits Hypoxia-Induced Angiogenesis via HIF-1 α /VEGF-A Pathway in Colorectal Cancer.Evidence-based complementary and alternative medicine : eCAM · 2015Article
- A proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinoma.Molecular cancer research : MCR · 2013Article
- Inhibition of autophagy enhances anticancer effects of bevacizumab in hepatocarcinoma.Journal of molecular medicine (Berlin, Germany) · 2013Article
- Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models.British journal of cancer · 2012Article
- Effects of Pien Tze Huang on angiogenesis in vivo and in vitro.Chinese journal of integrative medicine · 2012Article
- Metastatic gastric cancer - focus on targeted therapies.Biologics : targets & therapy · 2012Article
- Changes in the gene expression profile of A375 human melanoma cells induced by overexpression of multifunctional pigment epithelium-derived factor.Melanoma research · 2011Article
- Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer.Dose-response : a publication of International Hormesis Society · 2010Article
- Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy.Cancer research · 2010Review
- Monitoring Dual VEGF Inhibition in Human Pancreatic Tumor Xenografts With Dynamic Contrast-Enhanced Ultrasound.Technology in cancer research & treatmentArticle
- Angiogenesis inhibitors: current strategies and future prospects.CA: a cancer journal for cliniciansReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Neovascularization is one of the hallmarks associated with tumor growth. In the recent years, a number of angiogenesis inhibitors have been approved for clinical use in cancer patients. However, the efficacy of antiangiogenic therapy is in most cases short-lasting, with likely drug resistance developing within a few months. It is becoming clear also that there are a subset of malignant tumors that are inherently resistant to angiogenesis inhibition. The knowledge regarding resistance mechanisms towards angiogenesis inhibitors is still evolving and here we propose some theories and in some cases provide experimental evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.